GLYC GlycoMimetics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

GLYC [NASD]

GlycoMimetics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	2.24%	Shs Outstand	43.80M	Perf Week	-3.58%
Market Cap	153.72M	Forward P/E	-	EPS next Y	-1.31	Insider Trans	0.00%	Shs Float	24.50M	Perf Month	0.00%
Income	-49.70M	PEG	-	EPS next Q	-0.33	Inst Own	88.90%	Short Float	8.22%	Perf Quarter	-29.93%
Sales	9.00M	P/S	17.08	EPS this Y	-13.80%	Inst Trans	2.59%	Short Ratio	6.56	Perf Half Y	14.95%
Book/sh	3.33	P/B	0.97	EPS next Y	-12.00%	ROA	-29.70%	Target Price	-	Perf Year	-33.54%
Cash/sh	3.15	P/C	1.03	EPS next 5Y	-	ROE	-32.30%	52W Range	1.82 - 6.72	Perf YTD	-38.94%
Dividend	-	P/FCF	-	EPS past 5Y	-17.30%	ROI	-	52W High	-51.93%	Beta	2.41
Dividend %	-	Quick Ratio	15.80	Sales past 5Y	-	Gross Margin	-	52W Low	77.47%	ATR	0.19
Employees	57	Current Ratio	15.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.70	Volatility	5.88% 5.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	12.30%	Profit Margin	-	Rel Volume	1.43	Prev Close	3.22
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 31 AMC	Payout	-	Avg Volume	307.18K	Price	3.23
Recom	2.00	SMA20	-2.83%	SMA50	-7.06%	SMA200	-6.09%	Volume	439,491	Change	0.31%

Nov-14-19

Initiated

ROTH Capital

Buy

$12

Aug-05-19

Downgrade

SunTrust

Buy → Hold

$23 → $5

Aug-05-19

Downgrade

Piper Jaffray

Overweight → Neutral

$20 → $6

Aug-05-19

Downgrade

Jefferies

Buy → Hold

Apr-12-19

Initiated

Piper Jaffray

Overweight

$20

Dec-18-18

Initiated

H.C. Wainwright

Buy

$24

Jul-26-16

Initiated

SunTrust

Buy

Mar-17-15

Reiterated

Stifel

Buy

$13 → $14

Oct-12-20 07:28AM	Have Insiders Been Buying GlycoMimetics, Inc. (NASDAQ:GLYC) Shares? Simply Wall St.
Oct-06-20 10:31AM	GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status Zacks
08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga
Oct-05-20 04:30PM	FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease Business Wire
Sep-08-20 04:00PM	GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference Business Wire
Sep-04-20 09:00AM	GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-31-20 09:00AM	New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival Business Wire
Aug-28-20 08:56AM	How Much Is GlycoMimetics' (NASDAQ:GLYC) CEO Getting Paid? Simply Wall St.
Aug-06-20 05:19PM	3 Strong Buy Healthcare Stocks Under $5 That Could See Outsized Gains TipRanks
Jul-31-20 06:30PM	GlycoMimetics Inc (GLYC) Q2 2020 Earnings Call Transcript Motley Fool -5.06%
08:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020 Business Wire
Jul-24-20 09:15AM	GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020 Business Wire
Jul-22-20 10:45AM	Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation Simply Wall St.
Jul-10-20 09:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-30-20 06:30PM	Were Hedge Funds Right About Piling Into GlycoMimetics, Inc. (GLYC)? Insider Monkey
08:48AM	GlycoMimetics (GLYC) in Focus: Stock Moves 8.1% Higher Zacks
Jun-12-20 12:23PM	New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting Business Wire +12.36%
08:41AM	How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry Zacks
May-29-20 09:00AM	GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference Business Wire
May-15-20 12:30PM	GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020 Business Wire +7.61%
May-12-20 03:48AM	Edited Transcript of GLYC earnings conference call or presentation 1-May-20 12:30pm GMT Thomson Reuters StreetEvents -6.39%
May-08-20 08:30AM	GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders Business Wire +6.81%
May-05-20 07:18AM	Imagine Owning GlycoMimetics (NASDAQ:GLYC) And Trying To Stomach The 77% Share Price Drop Simply Wall St. -5.42%
May-01-20 09:01PM	GlycoMimetics Inc (GLYC) Q1 2020 Earnings Call Transcript Motley Fool
07:00AM	GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020 Business Wire
Apr-30-20 09:00AM	Compelling Data on Mechanism of Action for GlycoMimetics Late-stage Clinical Candidate Uproleselan Published in Nature Communications Business Wire
Apr-24-20 09:00AM	GlycoMimetics to Report First Quarter Financial Results on May 1, 2020 Business Wire
Apr-07-20 09:15AM	GlycoMimetics Appoints Dr. Myra Rosario Herrle as Vice President, Regulatory Affairs Business Wire
Apr-06-20 04:15PM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-26-20 01:51AM	Edited Transcript of GLYC earnings conference call or presentation 28-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Mar-11-20 07:36AM	Daniel Junius Is The Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) And They Just Spent US$68k On Shares Simply Wall St. -5.16%
Feb-28-20 08:07AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019 Business Wire
Feb-25-20 09:00AM	GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020 Business Wire -5.04%
Feb-11-20 07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-06-20 10:40AM	Wall Street Pros: These 3 Stocks Can Double Next Year TipRanks
Feb-04-20 09:53AM	GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations Business Wire
Jan-30-20 09:00AM	First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359 Business Wire
Jan-06-20 05:14PM	Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug. American City Business Journals
03:02PM	Md. biotech outlines path for blood cancer drug, including in China American City Business Journals
09:00AM	GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China Business Wire
Dec-19-19 11:09AM	Hedge Funds Dropped The Ball On GlycoMimetics, Inc. (GLYC) Insider Monkey
Nov-29-19 09:41AM	GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019 Business Wire
Nov-15-19 08:29PM	Edited Transcript of GLYC earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 09:00AM	GlycoMimetics to Present at Two Upcoming Investor Conferences Business Wire +5.03%
Nov-08-19 08:00AM	Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 08:24AM	GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments Business Wire +6.05%
Nov-06-19 10:03AM	GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting Business Wire
Oct-31-19 04:15PM	GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire -5.21%
Oct-30-19 05:23PM	GlycoMimetics, Inc. (GLYC) Is Burning These Hedge Funds Insider Monkey +7.74%
Sep-19-19 01:08PM	GlycoMimetics, Inc.'s (NASDAQ:GLYC) Single Biggest Risk For Investors Simply Wall St.
Aug-27-19 01:59AM	Edited Transcript of GLYC earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-18-19 06:25PM	Analysts Recommend These 2 Falling Knives GuruFocus.com
Aug-08-19 09:00AM	Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks
Aug-05-19 12:21PM	A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga -69.33%
08:56AM	GlycoMimetics stock down 53% after Phase 3 trial failure MarketWatch
06:34AM	GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails TheStreet.com
Aug-02-19 08:43PM	GlycoMimetics Reports Top-line Results From Pfizers Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire
07:24AM	GlycoMimetics (GLYC) Q2 2019 Earnings Call Transcript Motley Fool
Jul-25-19 09:00AM	GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire
Jul-23-19 10:23AM	GlycoMimetics Enters Oversold Territory Zacks
May-29-19 04:00PM	GlycoMimetics to Present at Jefferies 2019 Healthcare Conference Business Wire
May-20-19 05:15PM	Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-11-19 01:27PM	Heres What Hedge Funds Think About GlycoMimetics, Inc. (GLYC) Insider Monkey
May-06-19 09:00AM	GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire +5.21%
May-04-19 04:23PM	GlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 08:27AM	GlycoMimetics: 1Q Earnings Snapshot Associated Press
07:00AM	GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights Business Wire
06:30AM	GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-19 04:00PM	GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Business Wire
Apr-25-19 04:00PM	GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire
Apr-23-19 09:15AM	GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Business Wire
Apr-22-19 09:00AM	GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359 Business Wire
Apr-21-19 01:37AM	Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Apr-12-19 09:00AM	GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359 Business Wire
Apr-04-19 04:00PM	GlycoMimetics to Present at Upcoming Investor Conferences Business Wire
Mar-07-19 05:30PM	GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019 Business Wire
Mar-06-19 02:46PM	Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares? Simply Wall St.
12:56PM	GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:30AM	GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results Business Wire
06:30AM	GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-19 04:30PM	GlycoMimetics Announces Transition Plan for Board of Directors Business Wire
Feb-27-19 04:30PM	GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019 Business Wire
Feb-11-19 08:15AM	Detailed Research: Economic Perspectives on Waddell & Reed Financial, Kennametal, Automatic Data Processing, Trustmark, Eagle Bulk Shipping, and GlycoMimetics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-12-18 10:46AM	Heres What We Think About GlycoMimetics, Inc.s (NASDAQ:GLYC) CEO Pay Simply Wall St.
Dec-04-18 07:00AM	GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates Business Wire -5.55%
Dec-03-18 07:00AM	GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting Business Wire
Nov-29-18 09:15AM	GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018 Business Wire -5.61%
Nov-28-18 09:00AM	Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors Business Wire +5.21%
Nov-27-18 07:15AM	3 Top Biotech Stocks to Buy Right Now Motley Fool -8.93%
Nov-19-18 09:00AM	GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia Business Wire
Nov-16-18 03:27AM	Edited Transcript of GLYC earnings conference call or presentation 2-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-06-18 07:40AM	Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-02-18 07:39AM	GlycoMimetics: 3Q Earnings Snapshot Associated Press
07:30AM	GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements Business Wire
Nov-01-18 09:58AM	GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting Business Wire
Oct-26-18 09:00AM	GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018 Business Wire
Oct-24-18 09:00AM	GlycoMimetics to Present at Upcoming Investor Conferences Business Wire -13.47%
Oct-10-18 04:54PM	Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Aug-31-18 07:45AM	Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:00AM	Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT Thomson Reuters StreetEvents

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JUNIUS DANIEL M	Director	Mar 09	Buy	3.40	20,000	68,000	38,000	Mar 10 06:12 PM
Magnani John L.	SVP of Research, CSO	Jan 06	Option Exercise	1.12	106,983	119,821	289,760	Jan 06 06:23 PM
Magnani John L.	SVP of Research, CSO	Dec 20	Option Exercise	1.12	106,984	119,822	182,777	Dec 23 04:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience